TOP NEWS

Arcturus Therapeutics In Deal With Johnson & Johnson Innovation

San Diego-based RNA therapeutics developer Arcturus Therapeutics announced this morning that it is in a strategic collaboration deal, with Johnson & Johnson Innovation. The company said it has entered into a worldwide license agreement with Janssen Pharmaceuticals to develop and commercialize RNA-based drug products for specified diseases, using Arcturus' platform and technology. Financial terms of the deal were not disclosed, however, Arcturus said it will receive an upfront payment, R&D support, and pre-clinical, development and sales milestone payments, as well as royalties on future product sales. Plus, Janssen will assume responsibility for development and commercialization costs associated with the new program.


LATEST HEADLINES

More Headlines

BROWSE ISSUES